Core Insights - Virtuix Inc. will hold a conference call on March 5, 2026, to discuss its Q3 fiscal results for 2026 and provide updates on various initiatives [1][2] Company Updates - The company is joining the Made for Meta program, enhancing compatibility of its Omni One system with Meta Quest headsets and games [1] - Recent expansion of Omni One sales to Europe has been noted, indicating growth in international markets [1] - Integration of AI-driven Gaussian splatting technology into the Virtual Terrain Walk (VTW) system is a key development [1] Financial Information - The conference call will be hosted by CEO Jan Goetgeluk and CFO Thomas McGinnis, followed by a Q&A session [2] - A press release detailing the financial results will be issued prior to the call [1] Company Background - Virtuix Inc. is a leading manufacturer of full-body virtual reality systems, with a focus on consumer, enterprise, and defense markets [3] - The company's flagship product, the "Omni" omni-directional treadmill, allows users to walk and run in 360 degrees within virtual environments [3] - Virtuix is committed to innovation in XR and AI, aiming to deliver immersive experiences globally [3]

JERSEY CITY, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verisk Analytics, Inc. (Nasdaq: VRSK) (“Verisk” or the “Company”), a leading strategic data analytics and technology partner to the global insurance industry, today announced that it has entered into accelerated share repurchase agreements (“ASR Agreements”) with each of HSBC Bank USA, National Association and Wells Fargo Bank, National Association (the “ASR Counterparties”) to repurchase an aggregate of $1.5 billion of the Company’s common stock. After g ...

Agreement between QLE’s South African subsidiary and Necsa related to the siting, design, construction, commission and operation of an enrichment facility on the Necsa site in Pelindaba, with QLE’s objective to achieve market readiness for production of nuclear fuel The collaboration leverages QLE’s in-licensed and proprietary enrichment technology and Necsa’s globally-recognized production facilities DALLAS, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that on ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics E ...

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm ESTLeerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, ...

Core Viewpoint - PCI Biotech Holding ASA is proposing to dissolve the company and delist its shares from Euronext Oslo Børs due to the absence of operational activity and the expectation that such activity will not resume [2][3]. Group 1: Company Dissolution - The Board of Directors has proposed the resolution to dissolve PCI Biotech as there is no longer any operational activity within the company [2]. - The wholly owned subsidiary, PCI Biotech AS, has also resolved to initiate a parallel dissolution process [2]. Group 2: Delisting from Euronext Oslo Børs - The proposed resolution to delist the shares is based on the lack of operational activity and a limited asset base, leading the Board to conclude that the company is no longer suitable for public trading [3]. - The Board recommends that the delisting should occur as soon as possible [3].

Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate that targets and kills tumor cells by delivering a potent payload that binds to DNA [5]. - The FDA and EMA have approved ZYNLONTA for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [7][9]. Market Potential - ADC Therapeutics anticipates significant growth for ZYNLONTA starting in 2027, with potential peak revenue in the U.S. estimated to reach between $600 million to $1 billion annually, assuming compendia inclusion and regulatory approval [3]. - The confidence in ZYNLONTA's potential is bolstered by existing and upcoming clinical data, particularly in diffuse large B-cell lymphoma and other indolent lymphomas [3]. Company Background - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, focused on transforming treatment for patients through its portfolio, including ZYNLONTA [8]. - The company is headquartered in Lausanne, Switzerland, with operations in New Jersey, and is committed to driving innovation in ADC development [10].

Core Viewpoint - Rail Vision Ltd. has regained compliance with Nasdaq's minimum bid price requirement after its stock price was above $1.00 for 10 consecutive business days, resolving a previous non-compliance issue [1][2][3]. Company Overview - Rail Vision is an early commercialization stage technology company focused on enhancing railway safety and the rail data market through advanced artificial intelligence technology [4]. - The company's technology aims to save lives, increase efficiency, and significantly reduce costs for railway operators, while also contributing to the potential realization of autonomous trains [4].

Core Insights - North Media announced preliminary, unaudited financial results for 2025 and provided financial guidance for 2026 [1] Financial Performance for 2025 - Revenue for 2025 was DKK 1,296 million, aligning with the latest guidance of DKK 1,270 – 1,305 million [2] - EBITDA for 2025 was DKK 125 million, down 19% from the previous year, primarily due to integration costs of SDR and lower revenue in FK Distribution [2] - EBIT for 2025 was DKK 66 million, an improvement from DKK -75 million in 2024, with an EBIT margin of 5.2% [2] Segment Performance - In the Last Mile segment, revenue decreased by 1% to DKK 1,132 million, attributed to a decline in FK Distribution's volume, while SDR's revenue increased by 2% [2] - In the Digital Services segment, revenue grew by 1% to DKK 164 million, driven by a 4% increase in BoligPortal, despite a 13% decline in Dayli [3] - EBITDA in Digital Services improved to DKK 9 million from DKK -11 million in 2024, with EBIT rising to DKK 4 million from DKK -17 million in 2024 [3] Cost and Dividend Proposal - Unallocated costs for the Group were DKK 23 million, consistent with 2024 [4] - The Board proposed a dividend of DKK 1.25 per share, reflecting earnings from ordinary operations [4] Financial Guidance for 2026 - Revenue for 2026 is expected to be in line with 2025, with flat development in Last Mile and growth anticipated in Digital Services [5] - An increase in EBITDA and EBIT is expected across all companies, driven by strategic initiatives implemented in 2025 [5] - The annual report for 2025 is scheduled for publication on 25 February 2026 [5] Company Overview - North Media operates platforms that connect businesses and consumers, focusing on two core business areas: Last Mile and Digital Services [8] - Last Mile includes FK Distribution and SDR, leading distributors of leaflets and local newspapers in Denmark and Sweden [8] - Digital Services encompasses BoligPortal, Dayli, and Bekey, with potential for strong growth and scalability [8]

Company Overview - C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation (TPD) science to create innovative medicines that can transform patients' lives [3] - The company is developing targeted oncology programs through clinical studies and utilizes its TORPEDO platform to design and optimize small-molecule medicines for challenging diseases [3] - C4T's degrader medicines aim to leverage the body's natural protein recycling system to degrade disease-causing proteins, potentially addressing drug resistance and improving patient outcomes [3] Upcoming Events - C4T management will participate in the Barclays 28 Annual Global Healthcare Conference on March 10, 2026, at 8:00 AM ET in Miami, Florida, featuring a fireside chat [2] - The company will also present at the TD Cowen 46 Annual Healthcare Conference on March 3, 2026, at 11:50 AM ET in Boston, Massachusetts, where management will engage in a fireside chat [4]